| ²é¿´: 439 | »Ø¸´: 0 | |||
iningľ³æ (ÕýʽдÊÖ)
|
[½»Á÷]
ÈÕ±¾ÁøÉ¼»¨·Û±äÓ¦ÔÉàÏÂÆ¬¼ÁµÄ¼²²¡ÐÞÊÎ×÷ÓÃ
|
|
Ñо¿±³¾°£º ÔÚÈÕ±¾£¬ÈÕ±¾ÁøÉ¼£¨Japanese cedar£¬JC£©»¨·ÛÖ¢ÊÇÒ»ÖÖ³£¼ûµÄ±äÓ¦ÐÔ±ÇÑס£JC»¨·ÛÉàÏÂÃâÒßÖÎÁÆ£¨sublingual immunotherapy£¬SLIT£©Æ¬¼Á±»Åú×¼ÓÃÓÚJC»¨·ÛÖ¢µÄÖÎÁÆ¡£ Ñо¿Ä¿µÄ£º ÆÀ¹À5ÄêÄÚ£¨2014-2019Ä꣩£¬JC»¨·ÛSLITƬ¼ÁµÄ¼²²¡ÐÞÊÎ×÷Ó㬰üÀ¨3ÄêÁƳÌÓë2ÄêËæ·Ã¡£ Ñо¿·½·¨£º Ñо¿×ܹ²Èë×é1042Ãû5~64ËêJC»¨·ÛÖ¢»¼Õß¡£Ç°15¸öÔ¿ªÕ¹×î¼Ñ¼ÁÁ¿Ñо¿£¬Ö®ºó½«240Ãû¶ÔÕÕ×黼Õߣ¨placebo£¬P ×飩ÒÔ¼°236Ãû×î¼Ñ»îÐÔ¼ÁÁ¿×黼Õߣ¨active dose£¬A×飬5000ÈÕ±¾¹ýÃôµ¥Î»£©ÖØÐÂËæ»ú·Ö×飬·Ö±ð½ÓÊܶîÍâ18¸öÔÂÁƳÌPºÍAÖÎÁÆ£¨·Ö×éΪAA¡¢AP¡¢PA¡¢PPËÄ×飩¡£²ÉÓÃÿ¸öJC»¨·Û¼¾ÖÐÖ¢×´¸ß·åÆÚµÄ±Ç²¿Ö¢×´ºÍÒ©Îï×ÜÆÀ·Ö£¨total nasal symptom and medication score£¬TNSMS£©£¬ÆÀ¹ÀÈýÄêÁƳ̼°ÖÎÁÆÍ£Ö¹ºóÁ½Äê¹Û²ìÖл¼ÕßµÄÁÙ´²ÁÆÐ§¡£ Ñо¿½á¹û¼°½áÂÛ£º AA¡¢AP¡¢PAÈý×éTNSMS³ÊÏÖ³öÃ÷ÏÔ½µµÍ£»µ«ÊÇ£¬ AA×éÔÚÃâÒßÖÎÁƽ׶Σ¨µÚÈý¸ö»¨·Û¼¾£¬46.3%vsPP×飬P<.001£©ÒÔ¼°2ÄêËæ·Ã½×¶Î£¨µÚËĸö»¨·Û¼¾ºÍµÚÎå¸ö»¨·Û¼¾£¬·Ö±ðΪ45.3%ºÍ34.0%vsPP×飬P<.001£©ÆÀ·Ö½µµÍ¶¼Ïà¶Ô×îÃ÷ÏÔ¡£×î³£¼û²»Á¼·´Ó¦Îª¸øÒ©²¿Î»µÄÇá΢²»ÄÍÊÜ·´Ó¦¡£ JC»¨·ÛSLITƬ¼ÁÔÚÈýÄêÁƳÌÖоßÓгÖÐøµÄÁÙ´²ÁÆÐ§£¬²¢ÇÒÔÚÁƳÌÍ£Ö¹ºó¾ßÓÐÖÁÉÙ2ÄêµÄ¼²²¡ÐÞÊÎ×÷Óᣠ|
» ²ÂÄãϲ»¶
ͬһ²Î¿¼ÎÄÏ×ÒýÓöà´Î£¬Ôڲο¼ÎÄÏ×´¦Í¬Ò»±àºÅÏÔʾ¶à´Î
ÒѾÓÐ4È˻ظ´
Çó°×É«Á´Ã¹¾úStreptomyces albus J1074
ÒѾÓÐ6È˻ظ´
Ƥ·ô¼°Æä¸½ÊôÆ÷ÂÛÎÄÈóÉ«/·ÒëÔõôÊÕ·Ñ?
ÒѾÓÐ219È˻ظ´
Éú˿΢¾úÓÃʲôȾɫ¼Á
ÒѾÓÐ1È˻ظ´
̽Ë÷΢ÉúÎïÊÀ½çµÄ°ÂÃØÓëÇ°ÑØÑо¿£¬»¶Ó¹Ø×¢ÊɾúÌå¿ÆÑ§Ç°ÑØÏµÁв¥¿Í£¡
ÒѾÓÐ20È˻ظ´
ϵͳ¿ªÊ¼Î¬»¤ÁË£¬15ÈÕ½Ò°ñ£¿
ÒѾÓÐ3È˻ظ´
ÖпÆÔºÎ¢µç×ÓËù˶ʿѰÕÒMEMS\³¬Éù\ÉùÄ÷»òÕ߯äËû·½Ïò2026²©Ê¿»ú»á
ÒѾÓÐ0È˻ظ´
2026 applications for research assistant positions
ÒѾÓÐ0È˻ظ´













»Ø¸´´ËÂ¥